Walleye Capital LLC

Position in RGNX — REGENXBIO Inc.

CIK 1758720 NEW YORK, NY

Back to RGNX Full portfolio

Position in RGNX

as of Jun 30, 2026 · filed Aug 3, 2026 Compact

Position Value

$2,440,637

+$1,759,253 QoQ

Shares Held

203,726

+131.1% QoQ

Ownership

0.309%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

#39

of 163 holders

Holding Since

Sep 2021

5 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Common Shares in RGNX Over Time

Shares Held

Position Value (USD)

Derivatives in RGNX

reported options exposure · as of Sep 30, 2023

CallValue

$21,398

CallShares

1,300

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. RGNX ranks #38 (0.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	126,005	$33,608,053
2	CYTK	Cytokinetics Inc	239,728	$20,422,428
3	BMRN	Biomarin Pharmaceutical Inc	288,233	$16,492,692
4	IDYA	IDEAYA Biosciences, Inc.	386,183	$14,393,040
5	REGN	Regeneron Pharmaceuticals, Inc.	22,596	$14,089,509
6	RARE	Ultragenyx Pharmaceutical Inc.	334,854	$11,180,775
7	TYRA	Tyra Biosciences, Inc.	347,898	$11,111,862
8	BCAX	Bicara Therapeutics Inc.	353,226	$10,487,279

All Filings in RGNX

Export CSV

6 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,440,637	203,726	+131.1%	Shares	Sole	2026-08-03
2024-12-31	$681,384	88,148	+58.6%	Shares	Sole	2025-02-13
2024-06-30	$650,239	55,576	+411.9%	Shares	Sole	2024-08-14
2023-09-30	$178,706	10,857	-15.1%	Shares	Sole	2023-11-21
2023-09-30	$21,398	1,300	—	Call	Sole	2023-11-21
2021-09-30	$535,821	12,782	—	Shares	Sole	2021-11-15
No filing history on record for this holder in this stock.